These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 34063139)
1. A Validated LC-MS/MS Assay for the Simultaneous Quantification of the FDA-Approved Anticancer Mixture (Encorafenib and Binimetinib): Metabolic Stability Estimation. Attwa MW; Darwish HW; Al-Shakliah NS; Kadi AA Molecules; 2021 May; 26(9):. PubMed ID: 34063139 [TBL] [Abstract][Full Text] [Related]
2. A Rapid and Sensitive Liquid Chromatography-Tandem Mass Spectrometry Bioanalytical Method for the Quantification of Encorafenib and Binimetinib as a First-Line Treatment for Advanced (Unresectable or Metastatic) Melanoma-Application to a Pharmacokinetic Study. Hefnawy MM; Alanazi MM; Al-Hossaini AM; Alnasser AI; El-Azab AS; Jardan YAB; Attwa MW; El-Gendy MA Molecules; 2022 Dec; 28(1):. PubMed ID: 36615272 [TBL] [Abstract][Full Text] [Related]
3. Metabolic Stability Assessment of New PARP Inhibitor Talazoparib Using Validated LC-MS/MS Methodology: In silico Metabolic Vulnerability and Toxicity Studies. Attwa MW; Kadi AA; Abdelhameed AS; Alhazmi HA Drug Des Devel Ther; 2020; 14():783-793. PubMed ID: 32158196 [TBL] [Abstract][Full Text] [Related]
4. Estimation of zorifertinib metabolic stability in human liver microsomes using LC-MS/MS. Attwa MW; Al-Shakliah NS; AlRabiah H; Kadi AA; Abdelhameed AS J Pharm Biomed Anal; 2022 Mar; 211():114626. PubMed ID: 35123331 [TBL] [Abstract][Full Text] [Related]
5. Ultra-fast UPLC-MS/MS approach for estimating X-376 in human liver microsomes: Evaluation of metabolic stability via in silico software and in vitro analysis. Attwa MW; Abdelhameed AS; Kadi AA J Pharmacol Toxicol Methods; 2024; 128():107540. PubMed ID: 38996943 [TBL] [Abstract][Full Text] [Related]
6. An ultra-fast ultra-high-performance liquid chromatography-tandem mass spectrometry method for estimating the in vitro metabolic stability of palbociclib in human liver microsomes: In silico study for metabolic lability, absorption, distribution, metabolism, and excretion features, and DEREK alerts screening. Attwa MW; Abdelhameed AS; Kadi AA J Sep Sci; 2024 Aug; 47(15):e2400346. PubMed ID: 39087624 [TBL] [Abstract][Full Text] [Related]
7. Development and Validation of a Rapid LC-MS/MS Method for Quantifying Alvocidib: In Silico and In Vitro Metabolic Stability Estimation in Human Liver Microsomes. Attwa MW; AlRabiah H; Kadi AA Molecules; 2023 Mar; 28(5):. PubMed ID: 36903615 [TBL] [Abstract][Full Text] [Related]
8. LC-MS/MS method for the quantification of the anti-cancer agent infigratinib: Application for estimation of metabolic stability in human liver microsomes. Mostafa GAE; Kadi AA; AlMasoud N; Attwa MW; Al-Shakliah NS; AlRabiah H J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Aug; 1179():122806. PubMed ID: 34325312 [TBL] [Abstract][Full Text] [Related]
9. LC-MS/MS Estimation of Rociletinib Levels in Human Liver Microsomes: Application to Metabolic Stability Estimation. Attwa MW; Abdelhameed AS; Kadi AA Drug Des Devel Ther; 2021; 15():3915-3925. PubMed ID: 34552321 [TBL] [Abstract][Full Text] [Related]
10. Assessment of In Silico and In Vitro Selpercatinib Metabolic Stability in Human Liver Microsomes Using a Validated LC-MS/MS Method. Attwa MW; AlRabiah H; Mostafa GAE; Bakheit AH; Kadi AA Molecules; 2023 Mar; 28(6):. PubMed ID: 36985590 [TBL] [Abstract][Full Text] [Related]
11. LC-MS/MS Estimation of the Anti-Cancer Agent Tandutinib Levels in Human Liver Microsomes: Metabolic Stability Evaluation Assay. Attwa MW; Abdelhameed AS; Al-Shakliah NS; Kadi AA Drug Des Devel Ther; 2020; 14():4439-4449. PubMed ID: 33122888 [TBL] [Abstract][Full Text] [Related]
12. Development of an LC-MS/MS Method for Quantification of Sapitinib in Human Liver Microsomes: In Silico and In Vitro Metabolic Stability Evaluation. Attwa MW; AlRabiah H; Mostafa GAE; Kadi AA Molecules; 2023 Mar; 28(5):. PubMed ID: 36903565 [TBL] [Abstract][Full Text] [Related]
13. A validated LC-MS/MS analytical method for the quantification of pemigatinib: metabolic stability evaluation in human liver microsomes. Attwa MW; Abdelhameed AS; Alsaif NA; Kadi AA; AlRabiah H RSC Adv; 2022 Jul; 12(31):20387-20394. PubMed ID: 35919584 [TBL] [Abstract][Full Text] [Related]
14. Encorafenib and Binimetinib: First Global Approvals. Shirley M Drugs; 2018 Aug; 78(12):1277-1284. PubMed ID: 30117021 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of Alectinib Metabolic Stability in HLMs Using Fast LC-MS/MS Method: In Silico ADME Profile, P450 Metabolic Lability, and Toxic Alerts Screening. Attwa MW; AlRabiah H; Mostafa GAE; Kadi AA Pharmaceutics; 2023 Oct; 15(10):. PubMed ID: 37896209 [TBL] [Abstract][Full Text] [Related]
16. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628 [TBL] [Abstract][Full Text] [Related]
17. Identification of Iminium Intermediates Generation in the Metabolism of Tepotinib Using LC-MS/MS: In Silico and Practical Approaches to Bioactivation Pathway Elucidation. Abdelhameed AS; Attwa MW; Kadi AA Molecules; 2020 Oct; 25(21):. PubMed ID: 33126762 [TBL] [Abstract][Full Text] [Related]
18. Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma. Rose AAN Drugs Today (Barc); 2019 Apr; 55(4):247-264. PubMed ID: 31050693 [TBL] [Abstract][Full Text] [Related]
19. Assessment of the Attwa MW; AlRabiah H; Abdelhameed AS; Kadi AA Front Chem; 2024; 12():1323738. PubMed ID: 39391832 [TBL] [Abstract][Full Text] [Related]
20. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]